Company: CERO
Filing Date: 2025-04-28
Form Type: 10-K/A
Source: 0001213900-25-036075
Chunk: 38

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-28
Form: 10-K/A
Chunk 38
---
 of certain performance criteria; on December 2, 2024, the     
 board of directors confirmed that the performance criteria had been met with regards to one installment, resulting in the vesting of  
 1,275 shares and on February 24, 2025, the board of directors confirmed that the performance criteria has been met with regards       
 to the other installment, resulting in the vesting of the remaining 1,275 shares under (ii). Mr. Patel received $75,000 in consulting 
 fees pursuant to the agreement between Mr. Patel and the Company.                                                                     |

| (3) | This includes the option to purchase 1,125 shares of Common                                                                      
 Stock granted to the non-employee director on March 25, 2024 at an exercise price of $177.00 per share; such award was forfeited 
 following the director’s resignation from the board of directors.                                                                |

| (4) | This includes the non-employee director compensation for the                                        
 director for the period of service prior to the director’s resignation from the board of directors. |

19 On March 4, 2025, granted to each non-executive director options to purchase up to 35,845 shares of Common Stock, with 50% subject to vesting on the twelve-month anniversary of the date of grant and the remaining 50% subject to performance-based vesting conditions. Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters The following table sets forth information regarding the beneficial ownership of our common stock as of April 11, 2025, by:

| ● | each person known by us to be the beneficial owner of more than 5% of our outstanding shares of Common 
 Stock;                                                                                                 |

| ● | each of our named executive officers and directors that beneficially owns shares of our Common Stock; 
 and                                                                                                   |

| ● | all our executive officers and directors as a group. |

Beneficial ownership is determined in accordance with the rules and regulations of the SEC, which generally provide that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over that security. Shares of our Common Stock subject to options, warrants or shares of Series A Preferred Stock, Series B Preferred Stock or Series C Preferred Stock that are currently exercisable or convertible or exercisable or convertible within 60 days or shares of Common Stock underlying time-based restricted stock units that vest within 60 days are considered outstanding and beneficially owned by